GlassScriptPhysician profile
Meredith Wall Wagner
NPI 1316380694
$4,687.64
in general payments reported to CMS, 2019-2025
27 companies · $26.59 in 2025
The $26.59 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $541 · 2021: $860 · 2022: $1,532 · 2023: $863 · 2025: $26.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,043.85 | 2019-2023 | Skyrizi, Rinvoq, Botox |
| Pfizer INC. | $486.02 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $425.48 | 2019-2023 | |
| Janssen Biotech, INC. | $388.60 | 2019-2023 | Stelara, Simponi, Remicade |
| Genzyme Corporation | $382.85 | 2019-2023 | |
| Lilly USA, LLC | $309.07 | 2019-2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $248.70 | 2022-2023 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $231.74 | 2022-2023 | Ilumya |
| Prugen, INC. Pharmaceuticals | $193.88 | 2019 | |
| Amgen INC. | $125.68 | 2022-2023 | Otezla |
| Leo Pharma INC. | $108.09 | 2021-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.39 | 2020 | |
| Galderma Laboratories, L.P. | $83.15 | 2019-2022 | |
| Dermira, INC. | $80.57 | 2019-2020 | |
| Medimetriks Pharmaceuticals, INC. | $78.03 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $77.74 | 2019-2022 | |
| Incyte Corporation | $54.26 | 2022-2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $43.00 | 2020-2021 | |
| Genentech USA, INC. | $35.18 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.58 | 2019 | |
| Journey Medical Corporation | $34.24 | 2019-2022 | |
| Nabriva Therapeutics, Plc | $33.65 | 2022 | |
| Ucb, INC. | $26.96 | 2021 | |
| Notal Vision, INC. | $26.59 | 2025 | Foresee Home |
| Vyne Pharmaceuticals INC. | $20.18 | 2020 | |
| Biofrontera INC. | $18.51 | 2019 | |
| Dermavant Sciences, INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.